articleNeurologyFeb 9, 2019HYBRID OA

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response

JKJens KühleHKHarald KropshoferDHDieter HaeringUKUma KunduRMRolf Meinert

Novartis (Switzerland) · University of Freiburg · +1 more institution

PubMed
Indexed incrossrefpubmed

Abstract

Objective To assess the value of blood neurofilament light chain (NfL) as a biomarker of recent, ongoing, and future disease activity and tissue damage and its utility to monitor treatment response in relapsing-remitting multiple sclerosis. Methods We measured NfL in blood samples from 589 patients with relapsing-remitting multiple sclerosis (from phase 3 studies of fingolimod vs placebo, FREEDOMS and interferon [IFN]-β-1a, TRANSFORMS) and 35 healthy controls and compared NfL levels with clinical and MRI-related outcomes. Results At baseline, NfL levels (pg/mL) were higher in patients than in healthy controls (30.5 and 27.0 vs 16.9, p = 0.0001) and correlated with T2 lesion load and number of…

Citation impact

560
total citations
FWCI
41.31
Percentile
100%
References
24
Citations per year

Authors

10

Topics & keywords

Topics
Keywords
  • Fingolimod
  • Medicine
  • Multiple sclerosis
  • Internal medicine
  • Biomarker
  • Hazard ratio
  • Gastroenterology
  • Confidence interval
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding